CRIS Current Research Information System

LOLLINI, PIER LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.809
AS - Asia 10.275
EU - Europa 9.092
SA - Sud America 628
AF - Africa 608
OC - Oceania 17
Continente sconosciuto - Info sul continente non disponibili 7
Totale 32.436
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.602
VN - Vietnam 3.035
IT - Italia 2.915
CN - Cina 2.690
SG - Singapore 2.468
GB - Regno Unito 1.752
DE - Germania 998
HK - Hong Kong 644
SE - Svezia 615
FR - Francia 519
IN - India 436
BR - Brasile 425
UA - Ucraina 397
RU - Federazione Russa 387
CH - Svizzera 295
NL - Olanda 270
IE - Irlanda 256
KR - Corea 209
CI - Costa d'Avorio 202
JP - Giappone 193
ZA - Sudafrica 176
FI - Finlandia 129
BD - Bangladesh 128
CA - Canada 127
EE - Estonia 122
TG - Togo 93
BG - Bulgaria 66
ID - Indonesia 62
AR - Argentina 60
BE - Belgio 59
CO - Colombia 59
TH - Thailandia 53
PH - Filippine 52
MX - Messico 49
SC - Seychelles 46
PL - Polonia 44
TR - Turchia 44
JO - Giordania 43
IQ - Iraq 39
AT - Austria 38
RO - Romania 36
ES - Italia 33
GR - Grecia 33
PK - Pakistan 31
NG - Nigeria 27
LU - Lussemburgo 26
TW - Taiwan 26
CL - Cile 25
EC - Ecuador 23
LT - Lituania 22
EG - Egitto 21
SA - Arabia Saudita 19
HR - Croazia 16
AU - Australia 15
IR - Iran 14
PE - Perù 13
UZ - Uzbekistan 12
MY - Malesia 11
VE - Venezuela 11
AL - Albania 10
CR - Costa Rica 10
DZ - Algeria 10
AZ - Azerbaigian 9
DK - Danimarca 9
AE - Emirati Arabi Uniti 8
LB - Libano 8
MA - Marocco 7
KE - Kenya 6
PT - Portogallo 6
RS - Serbia 6
SK - Slovacchia (Repubblica Slovacca) 6
TN - Tunisia 6
CZ - Repubblica Ceca 5
KZ - Kazakistan 5
MD - Moldavia 5
UY - Uruguay 5
DO - Repubblica Dominicana 4
EU - Europa 4
GE - Georgia 4
HN - Honduras 4
HU - Ungheria 4
KH - Cambogia 4
LV - Lettonia 4
NI - Nicaragua 4
PY - Paraguay 4
TJ - Tagikistan 4
BO - Bolivia 3
IL - Israele 3
JM - Giamaica 3
MN - Mongolia 3
PS - Palestinian Territory 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AO - Angola 2
BY - Bielorussia 2
GH - Ghana 2
KG - Kirghizistan 2
LI - Liechtenstein 2
OM - Oman 2
SI - Slovenia 2
Totale 32.405
Salva come PNG Salva come JPEG
Città #
Singapore 1.694
Southend 1.447
Fairfield 1.210
Ashburn 1.172
Chandler 880
Ho Chi Minh City 651
Hong Kong 613
Bologna 588
Houston 583
Hanoi 576
Woodbridge 561
Wilmington 547
San Jose 505
Seattle 498
Hefei 489
Ann Arbor 451
Cambridge 387
Dong Ket 365
Princeton 360
Santa Clara 356
Beijing 302
Boardman 271
Jacksonville 257
Bern 253
Dublin 253
Council Bluffs 236
Shanghai 203
Abidjan 202
Lauterbourg 190
Milan 184
Seoul 179
Tokyo 170
Dallas 167
Los Angeles 166
Nanjing 155
Westminster 147
Padova 141
Frankfurt am Main 127
New York 118
Berlin 111
Rome 106
Buffalo 98
Lomé 93
Helsinki 89
Jinan 87
Haiphong 86
Turin 85
Bremen 79
Shenyang 76
Guangzhou 75
Da Nang 73
Saint Petersburg 73
San Diego 71
São Paulo 67
Sofia 65
Changsha 61
Nanchang 55
Mülheim 54
Brussels 53
Redwood City 52
Redondo Beach 51
London 49
Hebei 47
Tianjin 47
Amsterdam 46
Jakarta 46
Bengaluru 45
Phoenix 44
Amman 42
Redmond 41
Falkenstein 40
Jiaxing 40
Naples 39
Johannesburg 38
Medford 38
Biên Hòa 37
Toronto 37
Falls Church 36
Casalecchio di Reno 35
Des Moines 35
Hải Dương 35
Zhengzhou 34
Chicago 31
Verona 31
Warsaw 31
Can Tho 29
Lappeenranta 29
Mahé 29
Ottawa 29
Paris 29
Florence 27
Hangzhou 27
Montreal 27
Parma 27
Atlanta 26
Haikou 26
Yubileyny 26
Luxembourg 25
San Francisco 25
Vienna 25
Totale 20.664
Salva come PNG Salva come JPEG
Nome #
Vaccini antitumorali 997
IFN-γ and CD38 in Hyperprogressive Cancer Development 432
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER-2. 386
ROCK2 deprivation leads to the inhibition of tumor growth and metastatic potential in osteosarcoma cells through the modulation of YAP activity 376
Terapia genica 351
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft 340
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations 324
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma 285
Abstract 5909: IDH mutations in G2-3 conventional chondrosarcoma of bone: a mono institutional experience 274
Different mtDNA mutations modify tumor progression in dependence of the degree of respiratory complex I impairment 272
A multi-DNA preventive vaccine for p53/Neu driven cancer syndrome 267
Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells 260
Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases 258
Development of a K-edge micro CT for the study of tumor angiogenesis in small animals 254
Preclinical therapy of disseminated HER-2+ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus. 253
A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors 253
Cancer Vaccines Co-Targeting HER2/Neu and IGF1R 247
CD99 contributes to the EWS::FLI1 transcriptome by specifically affecting FOXM1-targets involved in the G2/M cell cycle phase, thus influencing the Ewing sarcoma genetic landscape 240
Rethinking herpes simplex virus: the way to oncolytic agents. 238
Virus-like particle display of HER2 induces potent anti-cancer responses 232
A Quinoline-Based DNA Methyltransferase Inhibitor as a Possible Adjuvant in Osteosarcoma Therapy 230
PD-L1 and IFN-γ modulate Non-Small Cell Lung Cancer (NSCLC) cell plasticity associated to immune checkpoint inhibitor (ICI)-mediated hyperprogressive disease (HPD) 229
Multiorgan Metastasis of Human HER-2+ Breast Cancer in Rag2−/−;Il2rg−/− Mice and Treatment with PI3K Inhibitor 228
CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity. 219
Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. 219
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression 219
ADK-VR2, a cell line derived from a treatment-naïve patient with SDC4-ROS1 fusion-positive primarily crizotinib-resistant NSCLC: a novel preclinical model for new drug development of ROS1- rearranged NSCLC 216
Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy 216
Tumoral immune-infiltrate (IF), PD-L1 expression and role of CD8/TIA-1 lymphocytes in localized osteosarcoma patients treated within protocol ISG-OS1 215
CD99 Acts as an Oncosuppressor in Osteosarcoma. 214
IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience 213
Cancer vaccines: Target antigens, vaccine platforms and preclinical models 211
Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma 211
Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity. 211
Functional evaluation of circulating anti-cancer antibodies with a 3D tumor cell growth inhibition assay 210
Bioprofiling TS/A Murine Mammary Cancer for a Functional Precision Experimental Model 206
Circulating miR34a levels as a potential biomarker in the follow-up of Ewing sarcoma 206
Cancer immunoprevention: from mice to early clinical trials 205
Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations 204
Insulin-like growth factor 2 mRNA-binding protein 3 is a novel post-transcriptional regulator of Ewing sarcoma malignancy 204
Endothelin-3 production by human rhabdomyosarcoma: A possible new marker with a paracrine role. 203
Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model. 203
Electroporated DNA vaccine clears away multifocal mammary carcinomas in her-2/neu transgenic mice. 202
A better immune reaction to Erbb-2 tumors is elicited in mice by DNA vaccines encoding rat/human chimeric proteins 199
HER-2/neu tolerant and non-tolerant mice for fine assessment of antimetastatic potency of dendritic cell-tumor cell hybrid vaccines 199
Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer 199
In silico modeling and in vivo efficacy of cancer preventive vaccinations 199
ImmunoGrid: Towards agent-based simulations of the human immune system at a natural scale 198
Lipid rafts, caveolae, and epidermal growth factor receptor family: friends or foes? 197
Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET. 197
Lamin A and the LINC complex act as potential tumor suppressors in Ewing Sarcoma 197
Evaluation of metastatic burden and recovery of human metastatic cells from a mouse model 196
A Mutation Threshold Distinguishes the Antitumorigenic Effects of the Mitochondrial Gene MTND1, an Oncojanus Function 193
The mechanisms of PD-L1 regulation in non-small-cell lung cancer (NSCLC): Which are the involved players? 193
CD99 drives terminal differentiation of osteosarcoma cells by acting as a spatial regulator of ERK 1/2. 192
Biological indicators of prognosis in Ewing’s sarcoma: an emerging role for lectin galactoside-binding soluble 3 binding protein (LGALS3BP). 192
An aza-macrocycle containing maltolic side-arms (maltonis) as potential drug against human pediatric sarcomas. 191
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice. 188
Immune targeting of autocrine IGF2 hampers rhabdomyosarcoma growth and metastasis 188
Targeting CD99 compromises the oncogenic effects of the chimera EWS-FLI1 by inducing re-expression of zyxin and inhibition of Gli1 activity 188
Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. 187
Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma. 187
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis 187
High metastatic efficiency of human sarcoma cells in Rag2/gamma c double knockout mice provides a powerful test system for antimetastatic targeted therapy 187
Engagement of CD99 activates distinct programs in Ewing sarcoma and macrophages 186
Synovial Sarcoma Preclinical Modeling: Integrating Transgenic Mouse Models and Patient-Derived Models for Translational Research 186
Antimetastatic activity of a preventive cancer vaccine. 186
Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy 185
Human responses against HER-2-positive cancer cells in human immune system-engrafted mice. 185
CRISPR/Cas9-mediated deletion of Interleukin-30 suppresses IGF1 and CXCL5 and boosts SOCS3 reducing prostate cancer growth and mortality 184
Oncolytic herpes virus retargeted to HER-2. 181
Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer 180
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response 180
Prevention and Therapy of Metastatic HER-2+ Mammary Carcinoma with a Human Candidate HER-2 Virus-like Particle Vaccine 179
Herpesviruses as oncolytic agents 179
ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis 178
Genetic algorithm against cancer. 178
Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4. 178
Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells 177
Modeling the competition between lung metastases and the immune system using agents. 177
CD99 isoforms dictate opposite functions in tumour malignancy and metastases by activating or repressing c-Src kinase activity 177
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis 176
Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas 174
Correction to: ABCA6 affects the malignancy of Ewing sarcoma cells via cholesterol-guided inhibition of the IGF1R/AKT/MDM2 axis 172
Immunoprevention and immunotherapy of mammary carcinoma 172
Vaccines for tumour prevention 170
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. 170
The Promise of Preventive Cancer Vaccines 170
Rhabdomyosarcomas are potential target of MAGE-specific immunotherapies. 169
Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. 169
Translational immunomics of cancer prevention. 168
Molecular Imaging of EGFR: It's Time to Go Beyond Receptor Expression 168
Evaluation of Modified PEG-Anilinoquinazoline Derivatives as Potential Agents for EGFR Imaging in Cancer by Small Animal PET. 166
A novel paradigm for cell and molecule interaction ontology: from the CMM model to IMGT-ONTOLOGY 164
Immunological prevention of a multigene cancer syndrome 164
NVE-BEZ235 as a new therapeutic option for sarcomas. 163
Inhibition of prostate carcinogenesis by combined active immunoprophylaxis. 162
TRAF6 regulates proliferation and differentiation of skeletal myoblasts 161
Expression levels of insulin receptor substrate-1 modulate the osteoblastic differentiation of mesenchymal stem cells and osteosarcoma cells. 161
Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis. 161
Totale 21.743
Salva come PNG Salva come JPEG
Categoria #
all - tutte 88.305
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 88.305
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021830 0 0 0 0 0 0 0 0 0 0 0 830
2021/20223.446 357 118 249 170 301 209 94 247 179 224 719 579
2022/20233.856 439 451 204 502 262 268 123 202 529 152 347 377
2023/20241.494 71 166 98 152 132 181 85 271 50 98 82 108
2024/20254.336 292 542 330 277 640 260 309 189 68 309 243 877
2025/202610.595 1.110 1.102 935 813 1.075 540 923 332 2.023 877 458 407
Totale 33.153